Cardiff Oncology, Inc. (CRDF)
NASDAQ: CRDF · IEX Real-Time Price · USD
2.250
-0.110 (-4.66%)
At close: Jul 19, 2024, 4:00 PM
2.280
+0.030 (1.33%)
Pre-market: Jul 22, 2024, 4:24 AM EDT
Cardiff Oncology Stock Forecast
Stock Price Forecast
The 2 analysts with 12-month price forecasts for Cardiff Oncology stock have an average target of 10.5, with a low estimate of 7.00 and a high estimate of 14. The average target predicts an increase of 366.67% from the current stock price of 2.25.
Analyst Consensus: Strong Buy
* Price targets were last updated on May 6, 2024.
Analyst Ratings
The average analyst rating for CRDF stock from 2 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Feb '24 | Mar '24 | Apr '24 | May '24 | Jun '24 | Jul '24 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 1 | 1 | 1 |
| Buy | 2 | 1 | 1 | 1 | 1 | 1 |
| Hold | 0 | 0 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 3 | 2 | 2 | 2 | 2 | 2 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Reiterates $14 | Strong Buy | Reiterates | $14 | +522.22% | May 6, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $12 → $14 | Strong Buy | Maintains | $12 → $14 | +522.22% | Mar 6, 2024 |
| Piper Sandler | Piper Sandler | Buy Maintains $5 → $7 | Buy | Maintains | $5 → $7 | +211.11% | Mar 1, 2024 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $13 → $12 | Strong Buy | Maintains | $13 → $12 | +433.33% | Aug 11, 2023 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $14 → $13 | Strong Buy | Maintains | $14 → $13 | +477.78% | Aug 8, 2023 |
Financial Forecast
Revenue This Year
399.08K
from 488.00K
Decreased by -18.22%
Revenue Next Year
68.00K
from 399.08K
Decreased by -82.96%
EPS This Year
-1.00
from -0.93
EPS Next Year
-1.08
from -1.00
Revenue Forecast
| Revenue | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 845,250 | 210,000 | n/a | 210,000 | 210,000 |
| Avg | 399,075 | 68,003 | n/a | 102,000 | 102,000 |
| Low | 196,000 | n/a | n/a | n/a | n/a |
Revenue Growth
| Revenue Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | 73.2% | -47.4% | - | - | 105.9% |
| Avg | -18.2% | -83.0% | - | - | - |
| Low | -59.8% | - | - | - | - |
EPS Forecast
| EPS | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | -0.89 | -0.84 | -1.21 | -1.94 | -2.36 |
| Avg | -1.00 | -1.08 | -1.36 | -1.89 | -2.30 |
| Low | -1.02 | -1.17 | -1.51 | -1.81 | -2.21 |
EPS Growth
| EPS Growth | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|
| High | - | - | - | - | - |
| Avg | - | - | - | - | - |
| Low | - | - | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.